The results of a study in which we were a site of a drug, ofatumumab, an anti-B-cell antibody, were reported at the AAN meeting. The drug showed marked reduction in MRI lesions. Patients receiving the drug had less than 1 new brain lesion per year, whereas placebo group had 16 lesions. The drug is now entering phase III trials, the last step before applying for FDA approval to market it in the United States.
For more information visit our website at www.fullertonneurocenter.com